Tue, Jun 27, 2017 | updated 09:35 PM IST

Immunotherapy shows positive results in metastatic bladder cancer treatment

Updated: Oct 09, 2016 13:47 IST      
Immunotherapy shows positive results in metastatic bladder cancer treatment

WashingtonD.C. [USA], Oct. 9 (ANI): Immunotherapy has shown promising results in the first and

second line treatment of metastatic bladder cancer in two phase trials, a recent research


Up to half of the patients with metastatic bladder cancer are not eligible for survival

prolonging first line treatment with cisplatin-based chemotherapy.

Survival in these patients is just nine to ten months with currently available alternative


The phase II KEYNOTE-052 trial1 evaluated the efficacy and safety of PD-1 blockade with

pembrolizumab as first line therapy in cisplatin ineligible patients with metastatic or locally

advanced bladder cancer.

The researchers presented the preliminary analysis of the first 100 patients enrolled in the


The primary endpoint of objective response rate was 24 percent.

The biomarker cut point to identify the patients, who are most likely to respond to the drug

was determined to be 10 percent or greater total PD-L1 expression in immune cells or tumor


Thirty patients had this level of expression of whom 11 (37 percent) responded to treatment.

The median duration of response has not yet been reached and treatment was well tolerated.

Lead author Arjun Balar, said: "Pembrolizumab has substantial activity with a favourable safety

profile as first line therapy in cisplatin ineligible patients with metastatic bladder cancer.

"The biomarker cut point will need to be validated in the larger study population, but seems to

identify patients most likely to respond to pembrolizumab well. Immunotherapy is rapidly

redefining our treatment approach for patients facing this dreadful disease," he added.

For several decades, there had been no global standard of care for second line treatment of

patients with metastatic bladder cancer who progress despite platinum-based chemotherapy until

the recent development of immune checkpoint blockade.

In another study, the phase II CheckMate 275 trial2 assessed the activity and safety of the

PD-1 inhibitor nivolumab in 270 patients with metastatic bladder cancer who have progressed

despite first line platinum-based chemotherapy.

CheckMate 275 is the largest study of a PD-1 inhibitor in bladder cancer reported to date.

In the 265 patients who could be evaluated for efficacy, the primary endpoint of objective

response rate was 19.6 percent.

The median duration of response has not yet been reached, with a median follow-up of seven


In both patients with tumors expressing higher and lower levels of PD-L1 (including those with

less than 1 percent PD-L1), the objective response rate was above that achieved historically

with chemotherapy.

"This data is being submitted to support registration of nivolumab for patients with metastatic

urothelial cancer that has progressed despite platinum-based chemotherapy, an indication for

which the US Food and Drug Administration has granted breakthrough therapy designation to

nivolumab," said lead author Professor Matthew Galsky.

"Immune checkpoint blockade has become the most promising approach for these patients," he


Commenting on the current management of bladder cancer, Maria De Santis, said, "There are

insufficient treatment options for patients ineligible for cisplatin and for those progressing

on cisplatin-based chemotherapy."

"This year the first immune check point inhibitor, atezolizumab, was approved for patients with

bladder cancer and CheckMate 275 provides similar results with nivolumab in the second line

setting," she said.

"KEYNOTE-052 confirms that immunotherapy is also active as first line therapy in cisplatin

ineligible patients, with a slightly lower response rate than chemotherapy. However, the

duration of response with pembrolizumab seems to exceed that of chemotherapy in historical

controls. The protocol included a new biomarker definition and cut-off which needs further

evaluation," said De Santis.

She concluded: "Immune check point inhibitors have started to alter the therapeutic landscape

for bladder cancer. We expect even more dramatic changes in the coming years with the use of

immunotherapy in other clinical stages and as combination therapy."

The study is presented in ESMO 2016. (ANI)

Washington D.C. [USA], June 27 (ANI): Relax your mind if you have a heart disease, as a study has found that people, who persistently experience moderate to severe mental distress are at increased risk of death.

Full Story >>

Washington D.C. [USA], June 27 (ANI): Beware if you work in late night shifts, as according to a study, working at night may hinder your body's ability to repair damaged DNA caused by normal cellular processes.

Full Story >>

Study finds why osteoarthritis is more common in females

Updated: Jun 27, 2017 07:31 IST     

Washington D.C. [USA], June 27 (ANI): Osteoarthritis -- a disease of joints -- is reported more among women than men. According to experts, fluid in the knee holds clues why women are more prone to it.

Full Story >>

Washington D.C. [USA], June 27 (ANI): According to a new study, premature infants still have a greater risk compared to full-term babies of dying of sudden infant death syndrome (SIDS) and other sleep-related infant deaths.

Full Story >>

Washington D.C. [USA], June 27 (ANI): A recent study has found that early antiretroviral treatment (ART) at the time of diagnosis may lead greater bone loss compared with deferring ART.

Full Story >>

Untreated polyarthritis can deform joints permanently

Updated: Jun 26, 2017 13:45 IST     

New Delhi [India], June 26 (ANI): Chikungunya, the bone breaking fever, being one of the reasons for polyarthritis , may become a rampant disorder.

Full Story >>

Education, training needed to help human trafficking victims

Updated: Jun 26, 2017 12:17 IST     

Washington D.C. [USA], Jun 26 (ANI): Knowing a little bit more about human trafficking could help save someone and so, a recent research has highlighted the need for education and training.

Full Story >>

Boozing makes ageing clock tick faster

Updated: Jun 26, 2017 10:57 IST     

Washington D.C. [USA], Jun 26 (ANI): Next time you reach for that glass of whiskey, you may want to rethink as a recent research has revealed that the more alcohol you drink, the more your cells appear to age.

Full Story >>

Improving cancer detection with help of body noise

Updated: Jun 26, 2017 07:40 IST     

Washington D.C. [USA], Jun 26 (ANI): According to a recent research, body's own 'seismic noise' can help improve the cancer detection.

Full Story >>

Wound healing goes up in cigarette smoke

Updated: Jun 26, 2017 07:35 IST     

Washington D.C. [USA], Jun 26 (ANI): When it comes to wound healing, vaping may be better than cigarette smoking, according to a recent research.

Full Story >>

Paracetamol during pregnancy can put unborn boys at risk

Updated: Jun 25, 2017 14:45 IST     

New Delhi [India] June 24, (ANI): Pregnant? You may want to rethink popping those paracetamol pills as a recent study has suggested that doing so can harm the masculinity of your unborn son.

Full Story >>

Excessive texting is bad for your wrists

Updated: Jun 25, 2017 11:48 IST     

New York [US], June 25 (ANI): Texting, the thing we do most with our phones, takes a toll on our health.

Full Story >>

Ozone exposure ups autism odds in at-risk people

Updated: Jun 24, 2017 19:47 IST     

Washington D.C. [USA], Jun 24 (ANI): Elevated exposure to ozone can put individuals with high levels of genetic variation at an even higher risk for developing autism than would be expected by adding the two risk factors together, according to a recent analysis.

Full Story >>

Washington D.C. [USA], June 24 (ANI): People suffering from advanced kidney cancer, we have some good news for you.

Full Story >>

Washington D.C. [USA], June 24 (ANI): In a recent study, leisure activities like going for a walk outside, reading, listening to music and other fun activities can reduce blood pressure for elderly caregivers of spouses with Alzheimer's disease.

Full Story >>

Anti-epilepsy drug to treat Alzheimer's disease?

Updated: Jun 24, 2017 10:09 IST     

Washington D.C. [USA], June 24 (ANI): According to a recent study, the scientists have tested an anti-epileptic drug for its potential impact on the brain activity of patients with mild Alzheimer's disease.

Full Story >>

Take these measures to keep oral cancer at bay

Updated: Jun 23, 2017 16:04 IST     

New Delhi [India], June 23 (ANI): Oral Cancer is one of the most prevalent forms of cancer in India. Evidence suggests that India bears the largest burden of oral cancers in the world, with an incidence of around 11.28 percent in Indian men.

Full Story >>

Don't eat but sleep, to beat office blues!

Updated: Jun 23, 2017 10:59 IST     

Washington D.C. [USA], June 23 (ANI): Stressful day at work leads to binge-eating at night. A new study suggests a good night's sleep can serve as a protecting factor between job stress and unhealthy eating in the evening.

Full Story >>

Washington D.C. [USA], June 23 (ANI): According to a recent clinical trial, intensive blood pressure lowering benefits patients with chronic kidney disease.

Full Story >>

New Delhi, [India], June 22 (ANI): J K Organization, in collaboration with Pushpawati Singhania Hospital and Research Institute Multispecialty Hospital, organized a two-day blood donation camp in New Delhi to collect 4043 units of blood.

Full Story >>